drugset / Trial / NCT02339090

Long-Acting Growth Hormone in Children Compared to Daily rhGH

NCT02339090

Phase 3 Completed 138 enrolled Versartis Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

The trial will compare a twice-monthly somavaratan dosing regimen for non-inferiority of treatment effect against daily injections of rhGH.

Timeline

Start
2015-08-26
Primary completion
2017-08-23
Completion
2017-08-23

Drugs

EvaluationDrugModalityDoseRoute
Comparator Somatropin Protein / enzyme biologic 34 ug/kg Subcutaneous
Subject Somavaratan Protein / enzyme biologic 3.5 mg/kg Subcutaneous

Indications

No indication recorded.